SCHEMBL2852262

SCHEMBL2852262

C=Cc1ccc(COc2ccc(C(C)(C)C)cc2Br)cc1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RXRA P19793 1/20 0.44
RXRB P28702 1/20 0.44
RXRG P48443 1/20 0.44
PTPN1 P18031 4/20 0.44
SMN1; SMN2 Q16637 4/20 0.44
RAB9A P51151 3/20 0.44
ALDH1A1 P00352 4/20 0.43
KMT2A Q03164 3/20 0.43
L3MBTL1 Q9Y468 3/20 0.43
NPSR1 Q6W5P4 2/20 0.43
MEN1 O00255 2/20 0.43
NPC1 O15118 1/20 0.43
HTT P42858 1/20 0.43
MAPT P10636 3/20 0.42
TSHR P16473 2/20 0.42
LMNA P02545 2/20 0.42
MAPK1 P28482 1/20 0.42
CASP3 P42574 1/20 0.42
SENP8 Q96LD8 1/20 0.42
SENP7 Q9BQF6 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12772153 0.81 SMN1; SMN2 (0.52) RXRARXRBRXRGPTPN1SMN1; SMN2
SCHEMBL22085284 0.81 SMN1; SMN2 (0.47) PTPN1SMN1; SMN2RAB9AALDH1A1L3MBTL1
SCHEMBL2846243 0.77 KMT2A (0.49) SMN1; SMN2RAB9AALDH1A1KMT2AL3MBTL1
SCHEMBL18555491 0.77 RXRA (0.41) RXRARXRBRXRGSMN1; SMN2RAB9A
SCHEMBL21310079 0.77 APP (0.64) RXRARXRBSMN1; SMN2RAB9AKMT2A
SCHEMBL14867054 0.77 APP (0.64) RXRARXRBSMN1; SMN2RAB9AKMT2A
SCHEMBL6475126 0.74 SMN1; SMN2 (0.40) PTPN1SMN1; SMN2RAB9AALDH1A1L3MBTL1
SCHEMBL21010320 0.74 ALDH1A1 (0.40) RXRARXRBRXRGSMN1; SMN2ALDH1A1
SCHEMBL3920762 0.73 MAPT (0.54) SMN1; SMN2RAB9AALDH1A1KMT2AL3MBTL1
SCHEMBL30883282 0.73 ALDH1A1 (0.52) SMN1; SMN2RAB9AALDH1A1KMT2AL3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100204038-A1 Catalysts based on metal complexes for the synthesis of optically active chrysanthemic acid CARLONI SILVIA 2010-08-12 US disclosed
EP-1765496-B1 CATALYSTS BASED ON COPPER COMPLEXES FOR THE SYNTHESIS OF OPTICALLY ACTIVE CHRYSANTHEMIC ACID ENDURA SPA (IT) 2010-07-14 EP disclosed
US-7723539-B2 Catalysts based on metal complexes for the synthesis of optically active chrysanthemic acid ENDURA S.P.A. (IT) 2010-05-25 US disclosed
US-20080021237-A1 Catalysts Based on Metal Complexes for the Synthesis of Optically Active Chrysanthemic Acid ENDURA S.P.A. (IT) 2008-01-24 US disclosed
EP-1765496-A1 CATALYSTS BASED ON METAL COMPLEXES FOR THE SYNTHESIS OF OPTICALLY ACTIVE CHRYSANTHEMIC ACID ENDURA S.p.A. (IT) 2007-03-28 EP disclosed
WO-2005123254-A1 CATALYSTS BASED ON METAL COMPLEXES FOR THE SYNTHESIS OF OPTICALLY ACTIVE CHRYSANTHEMIC ACID ENDURA S.P.A. (IT) 2005-12-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080021237-A1 Catalysts Based on Metal Complexes for the Synthesis of Optically Active Chrysanthemic Acid SCO2, ME1, ME3 RXRA 1044/4885RXRB 1940/4885RXRG 1134/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.